While it has been previously shown that JAK2 inhibition re-sensitizes NSCLC to EGFR inhibitors and G1T38 inhibits JAK2, the IC50 was >500 nm; a concentration that is too high for any biological relevance [40]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.